Abbvie Inc ABBV

$292.82 -1.73 (-0.59%)

Valuation

Market cap
521,499,712,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
22.95
P/E (forward)
21.06
Profit margin
6.91%
Debt to equity
-17.83

Trading

Volume
3,948,593
Avg volume
4,967,088
Day's range
$291.00 – $294.06
Shares out
1,767,616,000
Stochastic %K
62%
Beta
0.20
Analysts
Moderate Buy
Price target
$309.60

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

robcarroll Nov 17, 10:08 PM
$SLS and $ABBV https://tickerhall.com/p/116298260058644480
1 replies
rejuven8 Nov 17, 9:43 PM
$SLS this is an Abbvie $ABBV buyout candidate to replace their lost revenue of Veneteclax upcoming. You tell the doctor “no toxicity and 50% of patients live longer” that’s a no brainer.
1 replies
55X_ROI_Q1_2026 Nov 17, 9:42 PM
$SLS $330M in capital costs to date. A nice Tax Write off for $ABBV . . . . . . . . $200M Rare Priority Pediatric Review Voucher Cash on Hand $277M (post ) $IMGN Raised cash on the back of its P3 in PR/roc before it was bought for $10B .... In May of 2023 / before the Buyout in Dec //// ImmunoGen Announces Proposed Public Offering of ... 2023-05-03-ImmunoGen-Announces May 3, 2023 — it intends to offer and sell, $200 million of shares of its common stock in an underwritten public offering. https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won
0 replies
kim46 Nov 17, 6:13 PM 0 replies
55X_ROI_Q1_2026 Nov 17, 6:11 PM
$SLS $4B Market CAP / $20 per share $ABBV $IMGN $MRK The Revenue GPS will Generate just for the Initial AML CR2/3 Market is worth $120 Per Share. $6B Total Addressable Market for CR2/3 AML Will Set record patient uptake Rates / Pristine Safety Profile Easy in Home SubQ administration, low cost high margin manufacture, already TYPE -C FDA Approved. The FDA Already agreed to APPROVE GPS WITH A HR of .636 or Better --- FDA APPROVAL IS A DONE DEAL. THIS $20 Share Price is a FLEETING GIFT.
0 replies
55X_ROI_Q1_2026 Nov 17, 6:01 PM
$SLS $ABBV $IMGN $MRK ABBV Bought IMGN for $10B due to this P3 PR/ROC Trial Data 16.46 Month Median MOS GPS +Keytruda MOS is BETTER 18.4 Month Median Overall Survival. in Platinum Resistant / Refractory Ovarian cancer patients. Merck Dr/ Julie Cohen in co-authoring the P2 trial data, stated GPs + Key would be even more effective in an earlier macroscopic setting, like $MRNA 's trial. //
0 replies
55X_ROI_Q1_2026 Nov 17, 5:30 PM
$SLS $ABBV bought $IMGN for $10B Based on 16.46 Month MOS for Platinum Resistant Ovarian Cancer PROC GPS + $MRK Phase 2 MOS was 18.4 Months in mostly Platinum REFRACTORY SETTING --- OC Investors Know what that Means Gps is worth at LEAST $10B - Just for PR/ROC. Globally, hundreds of thousands of patients are diagnosed every year with cancers that overexpress WT1 (including over 300,000–400,000+ patients annually in the U.S. alone across major hematologic and solid malignancies). Its the future of the drug. https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won
0 replies
Gebinator Nov 17, 4:32 PM
$SLS the MEGA FLOSS 4: $JNJ $MRK $ABBV $LLY $40 Billy 🦖 MINIMUM
0 replies